Konica Minolta Healthcare Appoints New President and CEO
Fumi Hayashida, KMHA Fumi Hayashida, President and CEO, Konica Minolta Healthcare Americas, Inc.WAYNE, N.J., March 31, 2022 (GLOBE NEWSWIRE) --...
Fumi Hayashida, KMHA Fumi Hayashida, President and CEO, Konica Minolta Healthcare Americas, Inc.WAYNE, N.J., March 31, 2022 (GLOBE NEWSWIRE) --...
Results Support Further Exploration of Therapeutic Potential of Lomecel-B to Slow Cognitive Decline, Improve Quality of Life for Alzheimer’s Patients...
Preliminary safety data suggests lead iNKT agonists, PORT-2 and PORT-3, are well tolerated supporting continued development Company continues to work...
WARSAW, Ind., March 31, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on...
DALLAS, Texas, March 31, 2022 (GLOBE NEWSWIRE) -- Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) ("Rapid Therapeutic" or the "Company"),...
Addition of Dr. Beg provides Science 37 with expertise to apply more decentralized clinical trial methodologies to the industry’s largest...
Funds to support clinical development of INX-315, the company’s lead Cyclin-Dependent Kinase 2 inhibitor Sid Subramony, Ph.D., of Boxer Capital...
SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:...
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it...
Partners with Award-Winning Director Maya Albanese “Patch and Play” introduces the features of the Twirla (levonorgestrel and ethinyl estradiol) transdermal...
CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that...
EB-101 pivotal phase 3 VIITAL™ study in RDEB achieves target enrollment; top-line data expected in third quarter of 2022; gained...
Identification and elimination of $7.5 million of annualized run-rate costs, focusing on future growth and sustainable profitabilityCost optimization activities will...
Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show...
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX ‐ XLY) (OTCQX: CBWTF) ("Auxly" or the "Company"),...
BETHLEHEM, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home...
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA,...
WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple...
CHESTERBROOK, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and...
Amryt Supports World Lipodystrophy Day - March 31, 2022 DUBLIN, Ireland, and Boston MA, March 31, 2022, Amryt (Nasdaq: AMYT), a...